Blog
RSS FeedPosted by Michael Wonder on 16 Dec 2021
ICER publishes final evidence report and policy recommendations on tezepelumab for severe asthma
16 December 2021 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tezepelumab ...
Posted by Michael Wonder on 07 Oct 2021
ICER publishes evidence report on mavacamten for hypertrophic cardiomyopathy
7 October 2021 - Evidence is rated as promising but inconclusive to determine whether mavacamten provides a net health benefit for ...
Posted by Michael Wonder on 17 Aug 2021
ICER publishes final evidence report and policy recommendations on therapies for atopic dermatitis
17 August 2021 - Given uncertainty about safety data on oral JAK inhibitors for other indications, a narrow majority of the ...
Posted by Michael Wonder on 05 Aug 2021
ICER publishes final evidence report and policy recommendations on aducanumab for Alzheimer’s disease
5 August 2021 - Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net ...
Posted by Michael Wonder on 30 Jun 2021
In revised evidence report, ICER confirms judgment that evidence is insufficient to demonstrate net health benefit of aducanumab for patients with Alzheimer’s disease
30 June 2021 - Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, ...
Posted by Michael Wonder on 11 May 2021
ICER publishes final evidence report and policy recommendations on therapies for multiple myeloma
11 May 2021 - Independent appraisal committee unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel ...
Posted by Michael Wonder on 16 Apr 2021
ICER publishes final evidence report and policy recommendations on therapies for lupus nephritis
16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both ...
Posted by Michael Wonder on 05 Apr 2021
ICER publishes evidence report on therapies for multiple myeloma
5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially ...
Posted by Michael Wonder on 05 Mar 2021
ICER publishes final evidence report and policy recommendations on roxadustat
5 March 2021 - Independent appraisal committee determines the evidence is not adequate to demonstrate that roxadustat provides a net ...
Posted by Michael Wonder on 02 Mar 2021
ICER publishes Final Evidence Report and policy recommendations on new therapies for high cholesterol
2 March 2021 - For bempedoic acid, independent appraisal committee votes that the evidence is not adequate to demonstrate a net ...
Posted by Michael Wonder on 22 Jan 2021
ICER publishes evidence report on therapies for high cholesterol
22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a ...
Posted by Michael Wonder on 22 Jan 2021
ICER releases draft evidence report on therapies for lupus nephritis
22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 22 Nov 2020
ICER publishes final report and policy recommendations for haemophilia A therapies
20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...
Posted by Michael Wonder on 18 Oct 2020
ICER publishes final report and policy recommendations for targeted immune modulator therapies for ulcerative colitis
16 October 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of vedolizumab over adalimumab. ...
Posted by Michael Wonder on 27 Apr 2020
ICER releases evidence report on treatments for cystic fibrosis
27 April 2020 - Evidence on Trikafta provides high confidence of a substantial net health benefit for patients; additional benefits accrue ...